AHL Investment Management Inc. Boosts Holdings in Pfizer Inc. (NYSE:PFE)

AHL Investment Management Inc. grew its position in Pfizer Inc. (NYSE:PFE) by 1.3% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 74,103 shares of the biopharmaceutical company’s stock after buying an additional 936 shares during the period. Pfizer accounts for approximately 1.5% of AHL Investment Management Inc.’s investment portfolio, making the stock its 24th largest position. AHL Investment Management Inc.’s holdings in Pfizer were worth $2,073,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the company. Norges Bank acquired a new position in shares of Pfizer in the 4th quarter worth approximately $2,129,927,000. Wellington Management Group LLP lifted its holdings in shares of Pfizer by 4.9% in the 4th quarter. Wellington Management Group LLP now owns 239,209,768 shares of the biopharmaceutical company’s stock worth $6,886,849,000 after acquiring an additional 11,099,024 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its holdings in Pfizer by 8.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 104,246,432 shares of the biopharmaceutical company’s stock worth $2,985,783,000 after buying an additional 8,473,686 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in Pfizer by 13.8% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 68,506,441 shares of the biopharmaceutical company’s stock worth $1,972,300,000 after buying an additional 8,298,920 shares in the last quarter. Finally, Swedbank AB acquired a new stake in Pfizer during the 1st quarter worth approximately $172,902,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 0.4 %

Shares of NYSE PFE traded down $0.10 during mid-day trading on Monday, reaching $28.45. The company had a trading volume of 21,134,306 shares, compared to its average volume of 39,705,348. The company has a current ratio of 0.86, a quick ratio of 0.78 and a debt-to-equity ratio of 0.65. The firm has a 50 day simple moving average of $28.80 and a two-hundred day simple moving average of $27.86. The stock has a market cap of $161.21 billion, a P/E ratio of -475.59, a PEG ratio of 1.02 and a beta of 0.69. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $37.19.

Pfizer (NYSE:PFE) last issued its quarterly earnings data on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. During the same period last year, the firm posted $0.67 EPS. Pfizer’s revenue for the quarter was up 2.1% on a year-over-year basis. Sell-side analysts predict that Pfizer Inc. will post 2.68 earnings per share for the current year.

Pfizer Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 3rd. Shareholders of record on Friday, July 26th will be given a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a yield of 5.91%. The ex-dividend date is Friday, July 26th. Pfizer’s payout ratio is currently -2,799.53%.

Analysts Set New Price Targets

A number of research firms have issued reports on PFE. StockNews.com upgraded shares of Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Wells Fargo & Company increased their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Daiwa Capital Markets upgraded shares of Pfizer from a “neutral” rating to an “outperform” rating and increased their target price for the stock from $28.00 to $34.00 in a report on Wednesday, August 7th. Daiwa America upgraded shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Finally, UBS Group raised their price objective on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Eight analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and a consensus target price of $34.54.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.